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Presentations at this conference demonstrate that the commercialization of genetically 
engineered traits in specialty crops is a complicated process. Furthermore, university 
researchers are more accustomed to thinking about innovation as an event rather than as 
a process. Within Texas A&M AgriLife Research we are taking on the challenge of how 
to look at innovation as a process and how to steward innovation beyond simply publish-
ing, to create opportunities for our industry partners. In so doing, we are addressing a 
fundamental problem: the weakness of the pipeline.
University Culture
We are not trying to change the university, but rather to change the boundaries of what 
it can do, because university culture is vital and important for society. For us, innovation 
is about exporting something—our product. Every transaction with the world is about 
innovation. Resources come in; innovations go out. Although research is not a simple 
matter, conceptually it’s simple. Conducting research is complex. When research results 
are generated, they are interpreted and captured in a form that can be communicated as 
a channel to the marketplace. Principal investigators are a type of entrepreneur in that 
they convert resources from their stakeholders, federal and state agencies for the most 
part, and turn them into products: publications, which create professional success. It’s a 
well understood process.
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Corporate Culture
For corporations, innovation is about a product or a service. Regarding plant-biotech-
nology traits, the method of production is far more complex than just research. Even 
when a new trait has been evaluated and deregulated—having gone through the regulatory 
 approvals process—it still has to have a channel to the marketplace which involves having 
freedom to operate, involving patenting, and thorough understanding of the marketplace. 
It’s a dynamic process. 
The Contrast
Contrasting the two, one has a fairly quick turnaround whereas the other is like a slog 
through mud. The challenge for universities is to figure out how to be part of this whole 
process. Dennis Gonsalves1 talked about his work in terms of a public-sector anomaly. 
I give him a great deal of credit for having the fortitude to take on that task. A lot of 
researchers, not just those developing in plant biotech traits, are unwilling to face the 
challenges involved in commercialization. Publishing papers is a much more immediate 
fix. There’s nothing wrong with publishing, but if we are to work in plant biotechnol-
ogy, we should be ready to take on the challenge of being good stewards to the point of 
translating valuable opportunities to industry partners.
Universities: Thinking Differently
You cannot bring damaged goods to the game with industry. If a research result has been 
published, the ability to obtain patents is damaged, affecting the investment opportunity. 
The high cost of investment to obtain deregulation has been discussed by other speakers. 
Scott Thenell2 mentioned that the expense may be reduced by an order of magnitude; 
nevertheless, a lot of money would still be involved.
Criticisms leveled by the public and NGOs against genetically engineered crops 
 include:
• Big chemical companies are marketing these for profit.
• They are not in the best interests of consumers.
Big chemical companies are involved in these projects, because commercialization requires 
commitment and significant investment over a long period of time. On the other hand, 
if we can stand behind the traits that we’re developing, there’s an opportunity to build 
university/industry trust.
Why should universities be involved in this beyond publishing research papers? In 980 
the world changed as a result of the Bayh-Dole Act (BDA), which permits a university/
small business/non-profit institution to use federal research funding to pursue ownership 
of an invention; prior to the BDA, federal funding obligated inventors to assign inventions 
to the government. Universities responded by forming offices for intellectual property 
1Pages 37–46.
2Pages 83–94.
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management and technology transfer, which resulted in the formation of Association of 
University Technology Managers (AUTM), the first incarnation of which was the Society 
of University Patent Administrators (SUPA). At the time, they believed the important 
thing was to file patents, and this thinking set the stage. As a result, we now see universities 
carrying huge portfolios of unlicensed IP because patenting is the priority.
This is still a new process for universities, but it is endorsed by Texas A&M, which has 
the following mission statement:
To provide education, conduct research, commercialize technology, offer training, 
and deliver services for the people of Texas and beyond through its universities, 
state agencies and health science center.
The mission statement clarifies the importance of commercialization of technology, which 
is a consideration toward tenure in the Texas A&M University system.
Working Assumptions
We have the legacy of viewing innovation as a researcher-initiated and -driven event. 
Now the “eureka” moment is viewed as justification for commercialization. Often, the 
first thing that the researcher does, to ensure compliance with federal laws, is to go to the 
website and start filling out a form to disclose the invention. The next order of business 
is to file a patent and license it to someone and obtain a “commercialization” notch in 
the belt. This eventuality may not happen very often, but it’s a common framework, a 
baseline expectation; it is what the BDA says should happen. 
The Reality
On the other hand, this doesn’t fit well for biotech traits, because nowhere in this process 
have patenting and partnering strategies been developed. Universities do not typically 
engage in freedom-to-operate analyses, which is something that companies often have to 
deal with. Certainly, university researchers don’t think about freedom to operate when they 
are putting together gene constructs. We may receive an invention disclosure on a new 
trait composed of pieces and parts from six other collaborators, provided under individual 
material transfer agreements (MTAs) that preclude commercialization; complex conversa-
tions may be needed if the invention is to see the light of day. We have a distressed asset 
at that point, which is, unfortunately, not uncommon across universities.
A problem here is that universities are places for researchers who have decided that—for 
whatever reason—they don’t want to work in industry. Traditionally, professors have 
run self-directed programs of research within the support structure that the university 
provides. But, this is changing. Now we expect researchers to not only be experts in their 
fields, but also to be educated in commercialization and partnering with industry, which 
is unfair. My hat is off to productive scientists who have had the fortitude to negotiate 
the process of gaining regulatory approval. 
Many times, I have been approached by scientists with new, useful transgenic plants 
that they now wish to patent and on which they initially published data a couple of 
years before. In contrast, the people in the university patent office are less interested in 
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immediate usefulness than in whether the invention is novel and non-obvious, in which 
case they would have patented the invention two years before. Different ways of thinking 
are involved due to how researchers are schooled.
On the subject of schooling, it is a false premise that researchers simply need more 
education on intellectual property. The concept of a talent agent is relevant: artists, au-
thors and athletes all have agents. In contrast, researchers don’t have agents; they are on 
their own. Historically, scientists haven’t needed agents, whereas they now have to face 
the challenges of getting transgenics deregulated and marketing related technologies. 
Strategies are needed to ensure that assets are not damaged inadvertently through actions 
that may seem very reasonable from a research perspective. They should not be expected 
to be skilled in all subjects.
Culture Shifting
Managing innovation is not just about filing an invention disclosure, getting a patent and 
licensing it. One of the things that people often don’t appreciate is that, at a very early 
stage, a new innovation is not separable from the innovator. Therefore, if a researcher is not 
interested in innovation, there should be no negative consequence. The university should 
still allow the advancement of knowledge through publication. Professors should not be 
dictated to, should not feel forced to do something they are not comfortable with.
On the other hand, that comfort zone should not be overemphasized. Scientists should 
be encouraged to look for opportunities to transfer their research vision into results that 
may change the world. An important element of that change is leadership. Those in leader-
ship positions should not be saying, “Commercialization is not that important. Working 
with industry is not that important.” Within the Texas A&M University system, high-level 
leadership espouses the philosophy that commercialization is important. 
Although it is clear that researchers need assistance, sometimes they are unaware 
of that need. Also, deeds speak louder than words; it is important for us not to just 
philosophize, but actually show results. In 006, what was then the Texas Agricultural 
Experiment Station—now Texas A&M AgriLife Research—hired Bill McCutchen, who 
not only had industry experience but also had a track record as an innovator and as a 
researcher (Figure ). He was exactly what Texas A&M AgriLife needed to be able to 
effect the culture change.
Shortly after joining AgriLife, Bill hired Bob Avant (Figure ) to head up the bioen-
ergy effort, which is a pilot program to explore the concept of working with industry in 
 different ways. It has been enormously successful, and has matured such that we now have 
a corporate relations program. Bob has assembled a team who now work with industry as 
project managers and who act as intermediaries between our industry partners and our 
scientists who focus on research, and so we have project managers who mediate deliverables 
and assist in communication, because sometimes some translation is necessary.
In 007, I joined as the Director of Innovation Management and transformed the 
Office of Technology Commercialization as a liaison with Texas A&M AgriLife Research 
(Figure 3). I came from UC Berkeley where I’d had the opportunity to form the Industry 
Alliances Office, which tripled industry support for Berkeley in the first year. The simplest 
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Figure . Leadership in innovation–Bill McCutchen.
Figure . Strategic hire–Bob Avant.
way to describe what innovation management is at a university is to say that it’s the same 
as business development anywhere else. We have created three integrated teams:
• Innovation Management
 — They help researchers recognize opportunities and advance those opportuni-
ties through strategic planning.
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• Corporate Relations
 — They foster strategic partnering so that, instead of thinking about the rela-
tionship between industry and academia as just a way of outsourcing some 
research tasks, they create audacious collaborative projects to make exciting 
things happen.
• Technology Commercialization
 — Protecting intellectual property and assisting licensing, understanding that 
they need to focus; every time we say “yes” to something that isn’t any good, 
we are saying no to something that is. By setting priorities, they are masters at 
creating win-win arrangements with our industry partners.
Value Generation
From 003 to 007, things were pretty flat, but the creation of resources and infrastructure 
within Texas A&M AgriLife has met with success since then (Figure 4). The bar graph 
shows engagement from outside. The line graph shows engagement from inside.
There is opportunity for continued improvement; we’re still innovating in how we 
manage innovation, but we think that we are on the right track with an infrastructure 
that supports researchers. The first questions we have for them are:
• “What is it you’re trying to do?
• “What is your vision?”
• “How are you trying to change the world?”
And we are asking our industry partners:
• What is it that’s keeping you up at night?
• What are you trying to achieve?
Figure 3. Strategic hire–Peter Schuerman.
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Figure 4. Generating real value.
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The university is vast with much going on; it is impossible to keep track of it all. It’s like 
Google; we invite industry: “Give us some search terms. Tell us what it is you’re looking 
for.” Then we search within the university and put things together in a way that would be 
an impossible task for an individual researcher to take on. We broker these relationships. 
We identify opportunities, and then we make sure that our partners are being taken care 
of and we make sure that our researchers have the opportunity to participate in audacious, 
ambitious projects from which amazing things develop.
Texas AgriLife Research, having assembled the personnel and resources to steward 
traits from discovery to commercialization, is now the number-one Texas A&M System 
member for disclosures, licenses and royalties.
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